Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results
GlobeNewswire
Initiated a Phase 2 clinical trial of APG777, a subcutaneous half-life extended monoclonal antibody targeting IL-13, in patients..